Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Solbinsiran sodium by Eli Lilly and Co for Atherosclerosis: Likelihood of Approval
Solbinsiran sodium is under clinical development by Eli Lilly and Co and currently in Phase II for Atherosclerosis. According to...
Data Insights
Solbinsiran sodium by Eli Lilly and Co for Mixed Dyslipidemia: Likelihood of Approval
Solbinsiran sodium is under clinical development by Eli Lilly and Co and currently in Phase II for Mixed Dyslipidemia. According...